Business Wire

MA-EDB

Share
EDB Announces General Availability of BigAnimal, PostgreSQL Database in the Cloud

EDB , a leading contributor to PostgreSQL®, today announced the general availability of its BigAnimal™ offering, the first fully-managed PostgreSQL database in the cloud with compatibility for Oracle database technology. Built and backed by the world’s largest roster of PostgreSQL engineers, BigAnimal is for enterprises looking to deploy their most demanding databases into the cloud.

“BigAnimal was built in direct response to what our customers told us was missing from existing cloud Postgres offerings,” said EDB president and CEO, Ed Boyajian. “These improvements aren’t incremental - they’re transformational. We’ve made no compromises. This means you get fanatical attention from the biggest team in Postgres, native compatibility with Oracle database technology, and extreme high availability. And we run it all inside your cloud account.”

Accelerate Business with the Best Cloud PostgreSQL

Customers who are building serious cloud applications are realizing that they can’t get what they need from the basic PostgreSQL offerings available today. Without the transparency, control, and performance tuning required for their most demanding workloads, they are held back from moving fully into the cloud. BigAnimal responds to these needs by giving organizations granular control over the database within their own accounts and all the enterprise PostgreSQL capabilities EDB has been developing over the past 15 years - while being fully managed by EDB.

Specifically, with BigAnimal, enterprises will experience the following benefits:

  • Partner with PostgreSQL builders . For over a decade, PostgreSQL users have counted on EDB for their on-premises deployments. Now with BigAnimal, users can also rely on unequaled support from EDB’s world-class PostgreSQL experts.
  • Migrate applications on Oracle databases to PostgreSQL on Azure with little to no changes needed. With BigAnimal, customers can reduce costs, time, and risks when migrating workloads from legacy Oracle databases to cloud environments. BigAnimal’s deep compatibility with Oracle database technology and comprehensive migration tools address a critical need for enterprises who want to move quickly without leaving behind all their legacy database investments in code, skill sets, and resources.
  • Increase transparency and control of their cloud PostgreSQL . BigAnimal runs in a customer’s cloud account, allowing them to closely manage, secure, and optimize their PostgreSQL along with their other infrastructure according to their business needs and spend commitments. BigAnimal also gives users an unprecedented level of control over their PostgreSQL with superuser access to precisely tweak database internals.
  • Minimize complexity with the same PostgreSQL everywhere. EDB Postgres users can expect a uniform database experience, from EDB Postgres on premises to BigAnimal on Azure. This includes the ability to use their existing PostgreSQL skill sets, incorporate the database into their DevOps pipelines, and leverage EDB Postgres Advanced enterprise capabilities, such as enhanced security, performance management, and compatibility with Oracle database technology. With support for license portability, EDB also allows customers to easily deploy PostgreSQL whenever, wherever their business requires.

According to Carl Olofson, research vice president, Data Management Software, IDC: “In 2021, we saw a significant rise in cloud infrastructure spend and expect it to soon surpass non-cloud infrastructure. With this growing reliance on cloud platforms, many companies don’t have the in-house skills to deploy, manage, and optimize their databases. Considering EDB’s long track record of building and supporting Postgres, companies have a strong option for transitioning smoothly and optimizing their cloud database operations.”

For more information about EDB and BigAnimal and to sign up for a trial, please visit www.biganimal.com .

EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres and BigAnimal are trademarks of EnterpriseDB Corporation.

Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.

About EDB

PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release

79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha

Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release

Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly

Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release

Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit

Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release

New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye